hepatocellular carcinoma
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has approved Opdivo with Yervoy for the first-line treatment of adult patients with unresectable or ...
APRIL 14, 2025
FDA Approves Opdivo Qvantig for Subcutaneous Injection
The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...
DECEMBER 30, 2024
FDA Approves Tecentriq Hybreza for Subcutaneous Injection for All Adult Indications of IV Tecentriq
The FDA has approved Tecentriq Hybreza for subcutaneous injection as the intravenous formulation of Tecentriq.
SEPTEMBER 16, 2024
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 21, 2023
Survey Uncovers Barriers To HCC Surveillance
In the surveillance of patients with known risk factors for hepatocellular carcinoma, numerous obstacles exist on ...
JULY 8, 2022
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
MARCH 16, 2022
BMS Withdraws Opdivo Indication for HCC Monotherapy
In consultation with the FDA, Bristol Myers Squibb (BMS) has voluntarily withdrawn from the U.S. market the ...
JULY 27, 2021
Hep C Cure Linked to Lower Mortality From Liver Cancer
Curing he hepatitis C infection appears to dramatically improve five-year survival rates in people with liver ...
MARCH 17, 2020
Nivolumab-Ipilimumab Combo Approved to Treat Previously Treated HCC
The FDA granted accelerated approval for the use of nivolumab plus ipilimumab to treat hepatocellular carcinoma in ...
MARCH 12, 2020
FDA Grants Cabometyx New Indication for HCC
New treatment indicated for most common cause of liver cancer.
JANUARY 16, 2019
Keytruda Granted Accelerated Approval for Treatment of HCC
The FDA expanded the approved indications for pembrolizumab (Keytruda, Merck), granting the checkpoint inhibitor ...
NOVEMBER 16, 2018
FDA Approves New Indication for Lenvima for HCC
The FDA approved a new indication for Lenvima for first-line treatment of patients with unresectable hepatocellular ...
AUGUST 17, 2018